CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis

Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma

(2019) Nobuhide Higashino et al.   LABORATORY INVESTIGATION

Targeting Tumor-Associated Macrophages in Cancer

(2019) Paulina Pathria et al.   TRENDS IN IMMUNOLOGY

PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

(2018) Sarah Menguy et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Epidemiology of Esophageal Squamous Cell Carcinoma

(2018) Christian C. Abnet et al.   GASTROENTEROLOGY

Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients

(2018) De-Chen Lin et al.   GASTROENTEROLOGY

Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

(2018) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Tocopherols inhibit esophageal carcinogenesis through attenuating NF-κB activation and CXCR3-mediated inflammation

(2018) Hui Yang et al.   ONCOGENE

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

OUP accepted manuscript

(2018)   JNCI-Journal of the National Cancer Institute

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2018) Miguel F. Sanmamed et al.   CELL

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

(2018) Manish A. Shah et al.   JAMA Oncology

Targeting both tumour-associated CXCR2+neutrophils and CCR2+macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

(2017) Timothy M Nywening et al.   GUT

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

(2017) Toshihiro Kudo et al.   LANCET ONCOLOGY

Integrated genomic characterization of oesophageal carcinoma

(2017)   NATURE

Tumour-associated macrophages as treatment targets in oncology

(2017) Alberto Mantovani et al.   Nature Reviews Clinical Oncology

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

(2017) Yohei Masugi et al.   Cancer Immunology Research

Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment

(2016) Zhenyu Zhong et al.   CELL

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

(2016) Timothy M Nywening et al.   LANCET ONCOLOGY

The tumor microenvironment in esophageal cancer

(2016) E W Lin et al.   ONCOGENE

Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma

(2015) Xiaoguang Li et al.   GUT

CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages

(2015) Takanori Kitamura et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Impact of Inflammation–Metaplasia–Adenocarcinoma Sequence and Inflammatory Microenvironment in Esophageal Carcinogenesis Using Surgical Rat Models

(2014) Tomoharu Miyashita et al.   ANNALS OF SURGICAL ONCOLOGY

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

(2014) Carola H. Ries et al.   CANCER CELL

Global incidence of oesophageal cancer by histological subtype in 2012

(2014) Melina Arnold et al.   GUT

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

(2014) Susan J Dutton et al.   LANCET ONCOLOGY

Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers

(2014) Francois Moisan et al.   Molecular Oncology

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

(2014) Laura Bonapace et al.   NATURE

Genetic landscape of esophageal squamous cell carcinoma

(2014) Yi-Bo Gao et al.   NATURE GENETICS

The cellular and molecular origin of tumor-associated macrophages

(2014) R. A. Franklin et al.   SCIENCE

Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

(2013) D. E. Sanford et al.   CLINICAL CANCER RESEARCH

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Oesophageal carcinoma

(2013) Arjun Pennathur et al.   LANCET

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial

(2013) Thomas Crosby et al.   LANCET ONCOLOGY

Anti-tumour strategies aiming to target tumour-associated macrophages

(2012) Xiaoqiang Tang et al.   IMMUNOLOGY

Time-selective chemoprevention of vitamin E and selenium on esophageal carcinogenesis in rats: The possible role of nuclear factor kappaB signaling pathway

(2012) Hui Yang et al.   INTERNATIONAL JOURNAL OF CANCER

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet

(2010) H. Yang et al.   CARCINOGENESIS

Chemokine (C-C Motif) Ligand 2 Engages CCR2+Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone

(2009) Xin Lu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY